Indeed, the inhibition of EZH2 decreases FOXP3 expression on Treg cells, mitigating their immunosuppressive activity and promoting the recruitment of CD8+ T cells within the tumor microenvironment. The gene discussed is FOXP3; the disease is neoplasm.